Ask AI
INCA033989 in ET
Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential Thrombocythemia

Released: December 09, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: December 09, 2025